Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 16 de 16
1.
Med Chem ; 17(5): 453-461, 2021.
Article En | MEDLINE | ID: mdl-31840612

BACKGROUND: Quinazolines and quinazolinones constitute a major class of biologically active molecules, both from natural and synthetic sources. The quinazolinone moiety is an important pharmacophore showing many types of pharmacological activities as shown in recent exhaustive review on the chemistry of 2-heteroaryl & heteroalkyl-4-quinazolinones4-quinazolinones that are the formal condensation products of anthranilic acid and amides. They can also be prepared in this fashion through the Niementowski quinazolinone synthesis, named after it's discoverer Stefan Niementowski. Quinazoline and condensed quinazoline exhibit potent central nervous system (CNS) activities like anti-anxiety, analgesic, anti-inflammatory and anticonvulsant. Quinazolin-4- ones with 2, 3-disubstitution is reported to possess significant analgesic, anti-inflammatory and anticonvulsant activities. METHODS: To expand these views and application profiles, efforts have been made for the synthesis of a new class of quinazolinone by incorporating different amines into synthesized benzoxazinone ring by replacing O atom in the ring. Up till now, a great number of various procedures have been proposed for the synthesis of quinazolin-4-ones in the past few years. Using microwave radiation, this reaction could be easily and rapidly performed in very good yields, providing a large number of various 3-substituted-2- propyl-quinazolin-4-one derivatives which can be employed as useful bioactive compounds. We report a facile and efficient method for the synthesis of 3-substituted-2- propyl-quinazolin-4-one by the condensation reaction of anthranilic acid or halogen substituted anthranilic acid or methyl anthranilate, butanoic anhydride with various amines. We also report a drug/ligand or receptor/protein interactions by identifying the suitable active sites in the human gamma-aminobutyric acid receptor, the gaba (a)r-beta3 homopentamer human gammaaminobutyric acid receptor, and the gaba (a)r-beta3 homopentamer protein. RESULTS: It was observed in the reaction, 3-alkyl/aryl-2-alkyl-quinazolin-4-one gave good yield as well as good quality of the product by using MW. All the synthesized compounds were subjected to grid-based molecular docking studies. The results show that compound 4t has good affinity to the active site residue of the human gamma-aminobutyric acid receptor, and the gaba (a)r-beta3 homopentamer. CONCLUSION: The Microwave irradiation for the synthesis of the title compounds offers a reduction in reaction time, operation simplicity, cleaner reaction, easy work-up and improved yields. The procedure clearly highlights the advantages of green chemistry. The data reported in this article may be helpful for the medicinal chemists who are working in this area. The protein-ligand interaction plays a significant role in structural based drug designing. In the present work, we have docked the ligand, 2, 3-disubstituted quinazolinone with the proteins that are used as the target for GABA-A receptor.


GABA-A Receptor Antagonists/metabolism , Quinazolinones/metabolism , Receptors, GABA-A/metabolism , Catalytic Domain , GABA-A Receptor Antagonists/chemical synthesis , Humans , Microwaves , Molecular Docking Simulation , Protein Binding , Quinazolinones/chemical synthesis , Receptors, GABA-A/chemistry
2.
J Am Chem Soc ; 142(43): 18599-18618, 2020 10 28.
Article En | MEDLINE | ID: mdl-32991152

Here we interrogate the structurally dense (1.64 mcbits/Å3) GABAA receptor antagonist bilobalide, intermediates en route to its synthesis, and related mechanistic questions. 13C isotope labeling identifies an unexpected bromine migration en route to an α-selective, catalytic asymmetric Reformatsky reaction, ruling out an asymmetric allylation pathway. Experiment and computation converge on the driving forces behind two surprising observations. First, an oxetane acetal persists in concentrated mineral acid (1.5 M DCl in THF-d8/D2O); its longevity is correlated to destabilizing steric clash between substituents upon ring-opening. Second, a regioselective oxidation of des-hydroxybilobalide is found to rely on lactone acidification through lone-pair delocalization, which leads to extremely rapid intermolecular enolate equilibration. We also establish equivalent effects of (-)-bilobalide and the nonconvulsive sesquiterpene (-)-jiadifenolide on action potential-independent inhibitory currents at GABAergic synapses, using (+)-bilobalide as a negative control. The high information density of bilobalide distinguishes it from other scaffolds and may characterize natural product (NP) space more generally. Therefore, we also include a Python script to quickly (ca. 132 000 molecules/min) calculate information content (Böttcher scores), which may prove helpful to identify important features of NP space.


Cyclopentanes/chemistry , Furans/chemistry , GABA-A Receptor Antagonists/chemical synthesis , Ginkgo biloba/chemistry , Ginkgolides/chemistry , Bromides/chemistry , Cyclopentanes/chemical synthesis , Furans/chemical synthesis , GABA-A Receptor Antagonists/chemistry , Ginkgo biloba/metabolism , Ginkgolides/chemical synthesis , Isotope Labeling , Lactones/chemistry , Molecular Conformation , Oxidation-Reduction , Stereoisomerism
3.
Molecules ; 25(4)2020 Feb 24.
Article En | MEDLINE | ID: mdl-32102309

GABAA receptor modulators are structurally almost as diverse as their target protein. A plethora of heterocyclic scaffolds has been described as modulating this extremely important receptor family. Some made it into clinical trials and, even on the market, some were dismissed. This review focuses on the synthetic accessibility and potential for library synthesis of GABAA receptor modulators containing at least one heterocyclic scaffold, which were disclosed within the last 10 years.


GABA-A Receptor Agonists/chemical synthesis , GABA-A Receptor Antagonists/chemical synthesis , Heterocyclic Compounds/chemical synthesis , Receptors, GABA-A/chemistry , Small Molecule Libraries/chemical synthesis , Allosteric Regulation , Animals , Clinical Trials as Topic , GABA-A Receptor Agonists/pharmacology , GABA-A Receptor Antagonists/pharmacology , Heterocyclic Compounds/pharmacology , Humans , Molecular Structure , Small Molecule Libraries/pharmacology , Structure-Activity Relationship
4.
Int J Mol Sci ; 20(6)2019 Mar 21.
Article En | MEDLINE | ID: mdl-30901916

We previously published a series of 8-methoxypirazolo[1,5-a]quinazolines (PQs) and their 4,5-dihydro derivatives (4,5(H)PQ) bearing the (hetero)arylalkylester group at position 3 as ligands at the γ-aminobutyric type A (GABAA) subtype receptor. Continuing the study in this field, we report here the design and synthesis of 3-(hetero)arylpyrazolo[1,5-a]quinazoline and 3-(hetero)aroylpyrazolo[1,5-a]quinazoline 8-methoxy substituted as interesting analogs of the above (hetero)arylalkylester, in which the shortening or the removal of the linker between the 3-(hetero)aryl ring and the PQ was performed. Only compounds that are able to inhibit radioligand binding by more than 80% at 10 µM have been selected for electrophysiological studies on recombinant α1ß2γ2L GABAA receptors. Some compounds show a promising profile. For example, compounds 6a and 6b are able to modulate the GABAAR in an opposite manner, since 6b enhances and 6a reduces the variation of the chlorine current, suggesting that they act as a partial agonist and an inverse partial agonist, respectively. The most potent derivative was 3-(4-methoxyphenylcarbonyl)-8-methoxy-4,5-dihydropyrazolo[1,5-a] quinazoline 11d, which reaches a maximal activity at 1 µM (+54%), and it enhances the chlorine current at ≥0.01 µM. Finally, compound 6g, acting as a null modulator at α1ß2γ2L, shows the ability to antagonize the full agonist diazepam and the potentiation of CGS 9895 on the new α+/ß- 'non-traditional' benzodiazepine site.


GABA-A Receptor Agonists/chemical synthesis , GABA-A Receptor Antagonists/chemical synthesis , Pyrazoles/chemistry , Quinazolines/chemistry , Receptors, GABA-A/chemistry , Animals , Binding Sites , Cells, Cultured , Chemistry Techniques, Synthetic , GABA-A Receptor Agonists/chemistry , GABA-A Receptor Agonists/pharmacology , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Ligands , Molecular Structure , Protein Binding , Pyrazoles/pharmacology , Quinazolines/pharmacology
5.
Med Chem ; 15(1): 77-86, 2019.
Article En | MEDLINE | ID: mdl-29792150

BACKGROUND: Benzofurans are heterocyclic compounds with neurotropic activity. Some have been developed for the treatment of acute and degenerative neuronal injuries. OBJECTIVE: The study aimed to evaluate the in silico binding of some promising benzofurans on the GABA receptors, and the in vivo neurotropic activity of benzofuran analogues (BZF 6-10) of gamma-aminobutyric acid (GABA) on a seizure model. METHODS: The ligands with the best physicochemical attributes were docked on two GABA receptors (the alpha-1 subunit of GABAA-R and GBR1 subunit of GABAB-R). Selected benzofuran derivatives were synthesized by a multistep procedure and characterized. To examine the neurotropic effects, mice were pretreated with different concentrations of the compounds prior to PTZ- or 4- AP-induced seizures. We assessed acute toxicity, motor behavior, and the effects on seizures. RESULTS: The tested ligands that complied with Lipinski's rule of five were tested in silico with GABAA-R (ΔG = -5.51 to -5.84 kcal/mol) at the allosteric site for benzodiazepines. They bound to a similar cluster of residues as the reference compound (gaboxadol, ΔG = -5.51 kcal/mol). Synthesis was achieved with good overall yields (42-9.7%). Two compounds were selected for biological tests (BZF-7 and rac-BZF-10) on a mouse model of seizures, induced by pentylenetetrazol (PTZ) or 4-aminopyridine (4-AP). PTZ-induced seizures are associated with GABA receptors, and those 4-AP-induced with the blockage of the delayed rectifier-type potassium channel, which promotes the release of the NMDA-sensitive glutamatergic ionotropic receptor and other neurotransmitters. The biological assays demonstrated that BZF-7 and rac-BZF-10 do not protect against seizures. Indeed, BZF-7 increased the number of PTZ-induced seizures and decreased latency time. The 4-AP model apparently showed a potentiation of seizure effects after administration of the BZF-analogues, evidenced by the incidence and severity of the seizures and reduced latency time. CONCLUSION: The results suggest that the test compounds are GABAergic antagonists with stimulatory activity on the CNS.


Benzofurans/pharmacology , Central Nervous System Stimulants/pharmacology , GABA-A Receptor Antagonists/pharmacology , GABA-B Receptor Antagonists/pharmacology , Animals , Benzofurans/chemical synthesis , Benzofurans/chemistry , Benzofurans/toxicity , Central Nervous System Stimulants/chemical synthesis , Central Nervous System Stimulants/chemistry , Central Nervous System Stimulants/toxicity , GABA-A Receptor Antagonists/chemical synthesis , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/toxicity , GABA-B Receptor Antagonists/chemical synthesis , GABA-B Receptor Antagonists/chemistry , GABA-B Receptor Antagonists/toxicity , Humans , Ligands , Male , Mice , Molecular Docking Simulation , Receptors, GABA-A/chemistry , Receptors, GABA-B/chemistry
6.
J Am Chem Soc ; 140(24): 7445-7448, 2018 06 20.
Article En | MEDLINE | ID: mdl-29874068

Photoswitchable neurotransmitter receptors are powerful tools for precise manipulation of neural signaling. However, their applications for slow or long-lasting biological events are constrained by fast thermal relaxation of cis-azobenzene. We address this issue by modifying the ortho positions of azobenzene used in the tethered ligand. In cultured cells and intact brain tissue, conjugating inhibitory neurotransmitter receptors with one of the derivatives, dMPC1, allows bidirectional receptor control with 380 and 500 nm light. Moreover, the receptors can be locked in either an active or an inactive state in darkness after a brief pulse of light. This strategy thus enables both rapid and sustained manipulation of neurotransmission, allowing optogenetic interrogation of neural functions over a broad range of time scales.


Azo Compounds/metabolism , GABA-A Receptor Antagonists/metabolism , Receptors, GABA-A/metabolism , Synaptic Transmission/drug effects , Animals , Azo Compounds/chemical synthesis , Azo Compounds/chemistry , Azo Compounds/radiation effects , Cells, Cultured , Female , GABA-A Receptor Antagonists/chemical synthesis , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/radiation effects , Humans , Ligands , Male , Mice , Optogenetics/methods , Pregnancy , Stereoisomerism , Ultraviolet Rays
7.
J Am Chem Soc ; 139(28): 9637-9644, 2017 07 19.
Article En | MEDLINE | ID: mdl-28644021

11-O-Debenzoyltashironin (1) is a member of the neurotrophic sesquiterpenes, trace plant metabolites that enhance neurite outgrowth in cultured neurons. We report its synthesis in six steps from a butenolide heterodimer via its likely biosynthetic precursor, 3,6-dideoxy-10-hydroxypseudoanisatin, here identified as the chain tautomer of 1. Access to the tashironin chemotype fills a gap in a comparison set of convulsive and neurotrophic sesquiterpenes, which we hypothesized to share a common target. Here we show that both classes mutually hyperexcite rat cortical neurons, consistent with antagonism of inhibitory channels and a mechanism of depolarization-induced neurite outgrowth.


Bridged-Ring Compounds/chemical synthesis , GABA-A Receptor Antagonists/chemical synthesis , Animals , Bridged-Ring Compounds/chemistry , Bridged-Ring Compounds/pharmacology , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Dose-Response Relationship, Drug , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , HEK293 Cells , Humans , Molecular Structure , Neurons/drug effects , Neurons/metabolism , Rats , Receptors, GABA/metabolism , Stereoisomerism , Structure-Activity Relationship
8.
Org Biomol Chem ; 14(28): 6676-8, 2016 Jul 12.
Article En | MEDLINE | ID: mdl-27327397

The design and synthesis of azogabazine is described, which represents a highly potent (IC50 = 23 nM) photoswitchable antagonist of the GABAA receptor. An azologization strategy is adopted, in which a benzyl phenyl ether in a high affinity gabazine analogue is replaced by an azobenzene, with resultant retention of antagonist potency. We show that cycling from blue to UV light, switching between trans and cis isomeric forms, leads to photochemically controlled antagonism of the GABA ion channel.


GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Pyridazines/chemistry , Pyridazines/pharmacology , Azo Compounds/chemical synthesis , Azo Compounds/chemistry , Azo Compounds/pharmacology , Drug Design , GABA-A Receptor Antagonists/chemical synthesis , HEK293 Cells , Humans , Pyridazines/chemical synthesis , Receptors, GABA-A/metabolism
9.
Bioorg Med Chem Lett ; 26(9): 2147-51, 2016 May 01.
Article En | MEDLINE | ID: mdl-27032334

Two series of new derivatives of pyrrolidine-2,5-dione were synthesized and evaluated for their anticonvulsant properties. Initial screening for their anticonvulsant properties was performed in mice after intraperitoneal administration, using the maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) and 6-Hz seizure tests. Quantitative pharmacological research revealed that the highest level of protection was demonstrated by compound N-[{4-methylpiperazin-1-yl}-methyl]-3-(1-phenylethyl)-pyrrolidine-2,5-dione monohydrochloride (22) which was effective both in the scPTZ test (ED50=39 mg/kg) and in the 6-Hz test (ED50=36 mg/kg). This molecule showed higher potency than reference antiepileptic drugs such as ethosuximide, lacosamide and valproic acid. With the aim of explaining the possible mechanism of action of the selected molecule, its influence on sodium and calcium channels as well as NMDA and GABAA receptors binding properties were evaluated in vitro.


Anticonvulsants/pharmacology , Mannich Bases/pharmacology , Piperazines/pharmacology , Pyrrolidines/pharmacology , Succinimides/pharmacology , Animals , Anticonvulsants/chemical synthesis , Anticonvulsants/chemistry , Calcium Channel Blockers/chemical synthesis , Calcium Channel Blockers/chemistry , Calcium Channel Blockers/pharmacology , Calcium Channels, L-Type/metabolism , GABA-A Receptor Antagonists/chemical synthesis , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Mannich Bases/chemical synthesis , Mannich Bases/chemistry , Mice , Piperazines/chemical synthesis , Pyrrolidines/chemical synthesis , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Sodium Channel Blockers/chemical synthesis , Sodium Channel Blockers/chemistry , Sodium Channel Blockers/pharmacology , Structure-Activity Relationship , Succinimides/chemical synthesis , Succinimides/chemistry
10.
Eur J Pharmacol ; 764: 497-507, 2015 Oct 05.
Article En | MEDLINE | ID: mdl-26169564

Novel 2,3-benzodiazepine and related isoquinoline derivatives, substituted at position 1 with a 2-benzothiophenyl moiety, were synthesized to produce compounds that potently inhibited the action of GABA on heterologously expressed GABAA receptors containing the alpha 5 subunit (GABAA α5), with no apparent affinity for the benzodiazepine site. Substitutions of the benzothiophene moiety at position 4 led to compounds with drug-like properties that were putative inhibitors of extra-synaptic GABAA α5 receptors and had substantial blood-brain barrier permeability. Initial characterization in vivo showed that 8-methyl-5-[4-(trifluoromethyl)-1-benzothiophen-2-yl]-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one was devoid of sedative, pro-convulsive or motor side-effects, and enhanced the performance of rats in the object recognition test. In summary, we have discovered a first-in-class GABA-site inhibitor of extra-synaptic GABAA α5 receptors that has promising drug-like properties and warrants further development.


Anticonvulsants/pharmacology , Benzodiazepines/pharmacology , GABA-A Receptor Antagonists/pharmacology , Nootropic Agents/pharmacology , Receptors, GABA-A/drug effects , Animals , Anticonvulsants/chemical synthesis , Anticonvulsants/metabolism , Anticonvulsants/toxicity , Behavior, Animal/drug effects , Benzodiazepines/chemical synthesis , Benzodiazepines/metabolism , Benzodiazepines/toxicity , Blood-Brain Barrier/metabolism , Capillary Permeability , Disease Models, Animal , Dose-Response Relationship, Drug , GABA-A Receptor Antagonists/chemical synthesis , GABA-A Receptor Antagonists/metabolism , GABA-A Receptor Antagonists/toxicity , HEK293 Cells , Humans , Male , Mice , Molecular Structure , Motor Activity/drug effects , Nootropic Agents/chemical synthesis , Nootropic Agents/metabolism , Nootropic Agents/toxicity , Pentylenetetrazole , Rats, Sprague-Dawley , Receptors, GABA-A/genetics , Receptors, GABA-A/metabolism , Recognition, Psychology/drug effects , Seizures/chemically induced , Seizures/prevention & control , Structure-Activity Relationship , Xenopus laevis
11.
J Labelled Comp Radiopharm ; 56(3-4): 196-206, 2013.
Article En | MEDLINE | ID: mdl-24285326

The development of positron emission tomography radioligands for the GABAA /benzodiazepine receptor complex (GABAA receptor) labeled with (11) C and (18) F is examined. The review covers labeling strategies as well as brief biological evaluations of radioligands. In addition, we assess the special considerations that must be taken during a development program for radioligands targeting the GABAA receptor and explore some of the challenges that lie ahead.


Brain/diagnostic imaging , GABA-A Receptor Agonists/chemical synthesis , GABA-A Receptor Antagonists/chemical synthesis , Isotope Labeling , Radiopharmaceuticals/chemical synthesis , Receptors, GABA-A/metabolism , Animals , Carbon Radioisotopes/chemistry , Fluorine Radioisotopes/chemistry , GABA-A Receptor Agonists/pharmacology , GABA-A Receptor Antagonists/pharmacology , Humans , Positron-Emission Tomography , Radiopharmaceuticals/pharmacology
12.
Molecules ; 18(1): 894-913, 2013 Jan 11.
Article En | MEDLINE | ID: mdl-23344200

A new process for obtaining dibenzo[c,f][1,2,5]thiadiazepines (DBTDs) and their effects on GABA(A) receptors of guinea pig myenteric neurons are described. Synthesis of DBTD derivatives began with two commercial aromatic compounds. An azide group was obtained after two sequential reactions, and the central ring was closed via a nitrene to obtain the tricyclic sulfonamides (DBTDs). Whole-cell recordings showed that DBTDs application did not affect the holding current but inhibited the currents induced by GABA (I(GABA)), which are mediated by GABA(A) receptors. These DBTDs effects reached their maximum 3 min after application and were: (i) reversible, (ii) concentration-dependent (with a rank order of potency of 2c = 2d > 2b), (iii) mediated by a non-competitive antagonism, and (iv) only observed when applied extracellularly. Picrotoxin (which binds in the channel mouth) and DBTDs effects were not modified when both substances were simultaneous applied. Our results indicate that DBTD acted on the extracellular domain of GABA(A) channels but independent of the picrotoxin, benzodiazepine, and GABA binding sites. DBTDs used here could be the initial model for synthesizing new GABA(A) receptor inhibitors with a potential to be used as antidotes for positive modulators of these receptors or to induce experimental epilepsy.


GABA-A Receptor Antagonists/pharmacology , GABAergic Neurons/drug effects , Thiadiazines/pharmacology , Animals , Cells, Cultured , Female , GABA-A Receptor Antagonists/chemical synthesis , Guinea Pigs , Inhibitory Concentration 50 , Male , Membrane Potentials/drug effects , Myenteric Plexus/cytology , Patch-Clamp Techniques , Primary Cell Culture , Receptors, GABA-A/metabolism , Thiadiazines/chemical synthesis , gamma-Aminobutyric Acid/pharmacology
13.
Magn Reson Chem ; 49(12): 795-800, 2011 Dec.
Article En | MEDLINE | ID: mdl-22095873

DPA-713 is the lead compound of a recently developed 2-phenylpyrazolo[1,5-a]pyrimidineacetamide series that has been shown to display a good targeting capability toward peripheral benzodiazepine receptors, recently renamed translocator protein (18 kDa) or in short TSPO. On the basis of this structure, a novel derivative bearing a [(13)C]butynoate moiety has been designed and synthesized (three steps-42% overall yield) providing, upon rapid and quantitative para-hydrogenation, the corresponding hyperpolarized [(13)C]alkene. Para-hydrogen-induced polarization effects have been detected in both (1)H and (13)C-NMR spectra. Upon applying a field cycling procedure, the spin order of para-H(2) added hydrogens is transferred on the (13)C carboxylate moiety yielding a signal enhancement of approximately 4500 times. T(1) of the carboxylate carbon atom is approximately 21.9 s (at 9.37 T). A (13)C-MR image has been acquired by using the (13)C RARE (Rapid Acquisition by Relaxation Enhancement) acquisition protocol on a 10-mM solution. The main limitation to the in vivo use of this novel para-hydrogenated [(13)C]derivative is its relatively low solubility in aqueous systems.


Acetamides/chemical synthesis , Carbon Isotopes/chemistry , Esters/chemical synthesis , GABA-A Receptor Antagonists/chemical synthesis , Hydrogen/metabolism , Isotope Labeling/methods , Magnetic Resonance Imaging/methods , Pyrazoles/chemical synthesis , Pyrimidines/chemical synthesis , Receptors, GABA/metabolism , Acetamides/metabolism , Acetamides/pharmacology , Carbon Isotopes/analysis , Chromatography, Thin Layer , Esters/metabolism , Esters/pharmacology , GABA-A Receptor Antagonists/metabolism , GABA-A Receptor Antagonists/pharmacology , Humans , Hydrogen/chemistry , Hydrogenation , Magnetic Resonance Spectroscopy , Pyrazoles/metabolism , Pyrazoles/pharmacology , Pyrimidines/metabolism , Pyrimidines/pharmacology , Receptors, GABA/chemistry , Solubility , Water
14.
Bioorg Med Chem Lett ; 21(14): 4252-4, 2011 Jul 15.
Article En | MEDLINE | ID: mdl-21664131

A selection of highly potent analogues based on the gabazine structure is described. Their syntheses are carried out in just four steps, and their potencies for antagonism at the GABA(A) receptor were measured. All antagonists showed significantly higher potencies compared to the parent competitive antagonist, gabazine.


GABA-A Receptor Antagonists/chemical synthesis , Pyridazines/chemistry , Receptors, GABA-A/chemistry , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Pyridazines/chemical synthesis , Pyridazines/pharmacology , Receptors, GABA-A/metabolism
15.
Bioorg Med Chem ; 19(9): 2927-38, 2011 May 01.
Article En | MEDLINE | ID: mdl-21498079

Positive modulators at the benzodiazepine site of α2- and α3-containing GABA(A) receptors are believed to be anxiolytic. Through oocyte voltage clamp studies, we have discovered two series of compounds that are positive modulators at α2-/α3-containing GABA(A) receptors and that show no functional activity at α1-containing GABA(A) receptors. We report studies to improve this functional selectivity and ultimately deliver clinical candidates. The functional SAR of cinnolines and quinolines that are positive allosteric modulators of the α2- and α3-containing GABA(A) receptors, while simultaneously neutral antagonists at α1-containing GABA(A) receptors, is described. Such functionally selective modulators of GABA(A) receptors are expected to be useful in the treatment of anxiety and other psychiatric illnesses.


Receptors, GABA-A/chemistry , Allosteric Regulation , Anti-Anxiety Agents/chemical synthesis , Anti-Anxiety Agents/chemistry , Anti-Anxiety Agents/pharmacology , Benzodiazepines/chemistry , GABA-A Receptor Antagonists/chemical synthesis , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/pharmacology , Heterocyclic Compounds, 2-Ring/chemistry , Quinolines/chemistry , Receptors, GABA-A/metabolism , Structure-Activity Relationship
16.
Bioorg Med Chem ; 18(21): 7548-64, 2010 Nov 01.
Article En | MEDLINE | ID: mdl-20888240

A series of 3,6-disubstituted ß-carbolines was synthesized and evaluated for their in vitro affinities at α(x)ß(3)γ(2) GABA(A)/benzodiazepine receptor subtypes by radioligand binding assays in search of α(1) subtype selective ligands to treat alcohol abuse. Analogues of ß-carboline-3-carboxylate-t-butyl ester (ßCCt, 1) were synthesized via a CDI-mediated process and the related 6-substituted ß-carboline-3-carboxylates 6 including WYS8 (7) were synthesized via a Sonogashira or Stille coupling processes from 6-iodo-ßCCt (5). The bivalent ligands of ßCCt (32 and 33) were also designed and prepared via a palladium-catalyzed homocoupling process to expand the structure-activity relationships (SAR) to larger ligands. Based on the pharmacophore/receptor model, a preliminary SAR study on 34 analogues illustrated that large substituents at position-6 of the ß-carbolines were well tolerated. As expected, these groups are proposed to project into the extracellular domain (L(Di) region) of GABA(A)/Bz receptors (see 32 and 33). Moreover, substituents located at position-3 of the ß-carboline nucleus exhibited a conserved stereo interaction in lipophilic pocket L(1), while N(2) presumably underwent a hydrogen bonding interaction with H(1). Three novel ß-carboline ligands (ßCCt, 3PBC and WYS8), which preferentially bound to α1 BzR subtypes permitted a comparison of the pharmacological efficacies with a range of classical BzR antagonists (flumazenil, ZK93426) from several different structural groups and indicated these ß-carbolines were 'near GABA neutral antagonists'. Based on the SAR, the most potent (in vitro) α(1) selective ligand was the 6-substituted acetylenyl ßCCt (WYS8, 7). Earlier both ßCCt and 3PBC had been shown to reduce alcohol self-administration in alcohol preferring (P) and high alcohol drinking (HAD) rats but had little or no effect on sucrose self-administration.(1-3) Moreover, these two ß-carbolines were orally active, and in addition, were anxiolytic in P rats but were only weakly anxiolytic in rodents. These data prompted the synthesis of the ß-carbolines presented here.


Alcoholism/drug therapy , Benzodiazepines/chemistry , Carbolines/chemistry , GABA-A Receptor Antagonists/chemical synthesis , Receptors, GABA-A/chemistry , Animals , Binding Sites , Carbolines/chemical synthesis , Carbolines/therapeutic use , Cell Line , Computer Simulation , GABA-A Receptor Antagonists/chemistry , GABA-A Receptor Antagonists/therapeutic use , Humans , Protein Subunits/antagonists & inhibitors , Protein Subunits/metabolism , Rats , Receptors, GABA-A/metabolism , Stereoisomerism , Structure-Activity Relationship
...